Eli Lilly agrees to acquire AtaiBeckley, a psychedelics-focused biotech, in a deal reported by multiple outlets as starting at about $2.8 billion and potentially rising to as much as $3.8 billion depending on the structure and timing of additional payments. The acquisition is framed as part of Lilly’s efforts to expand its neuroscience and mental-health pipeline as experimental treatments based on psychedelics gain broader interest.
Several reports say the upfront consideration is $2.8 billion. Others describe the total potential value as higher, citing a larger cap or additional milestones that could increase the final price. In premarket trading, AtaiBeckley’s shares reportedly surge after news of the talks broke, with one outlet citing a sharp rise in early trading.
The reports also characterize AtaiBeckley’s work as involving psychedelic compounds and related experimental treatments, including drug candidates associated with DMT and MDMA. Collectively, the coverage indicates Lilly is seeking to bring AtaiBeckley’s programs into its broader drug development portfolio, while the exact final deal value depends on terms not fully detailed across the reports.
